Eradicating Helicobacter pylori in non-ulcer dyspepsia may not be cost effective [11]

British Medical Journal

Volumn 322, Issue 7285, 2001, Pages 557-

  Formoso, G ^a   Maestri, E ^a   Magrini, N ^a   Koch, M ^a   Capurso, L ^a   Liberati, A ^a  

^a Ctr Eval Effectiveness Hlth Care   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; DISEASE SEVERITY; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STOMACH ACID SECRETION;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; META-ANALYSIS;

EID: 0035799062     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
2. Lack of effect of treating Helicobacter pylori in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group
3. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia
4. The Glasgow dyspepsia seventy score - A tool for the global measurement of dyspepsia
5. Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication